Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children

Petra M C Callenbach; Lise P M Pels; Paul G H Mulder; Wim H J P Linssen; Rob H J M Gooskens; Jan L van der Zwan; Oebele F Brouwer; SUM30042 Trial Group

doi:10.1016/j.ejpn.2007.02.010

Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children

Eur J Paediatr Neurol. 2007 Nov;11(6):325-30. doi: 10.1016/j.ejpn.2007.02.010. Epub 2007 Apr 10.

Authors

Petra M C Callenbach¹, Lise P M Pels, Paul G H Mulder, Wim H J P Linssen, Rob H J M Gooskens, Jan L van der Zwan, Oebele F Brouwer; SUM30042 Trial Group

Affiliation

¹ Department of Neurology, University Medical Centre Groningen, University of Groningen, P.O. Box 30 001 9700 RB Groningen, The Netherlands. p.m.c.tijink@neuro.umcg.nl

PMID: 17428708
DOI: 10.1016/j.ejpn.2007.02.010

Abstract

About 4-10% of children and adolescents suffer from migraine. In the last few years, several studies have been performed to assess the efficacy and safety of triptans for the acute treatment of migraine in children and adolescents. Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe. This review describes the results of the studies with sumatriptan nasal spray that have been performed in children and adolescents, including a study performed in the Netherlands.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Administration, Intranasal
Adolescent
Child
Child, Preschool
Clinical Trials as Topic
Humans
Migraine Disorders / drug therapy*
Serotonin Receptor Agonists / administration & dosage*
Sumatriptan / administration & dosage*

Substances

Serotonin Receptor Agonists
Sumatriptan